Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m(2)) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

BACKGROUND: The recommended starting dose of cabazitaxel for castration-resistant prostate cancer (CRPC) is 25 mg/m(2) in Japan and Europe. Although lower doses are established alternatives based on randomized controlled trials, the safety and efficacy of 25 and 20 mg/m(2) in real-world settings are...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuyama, Hideyasu, Matsubara, Nobuaki, Kazama, Hirotaka, Seto, Takeshi, Tsukube, Shoko, Suzuki, Kazuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359263/
https://www.ncbi.nlm.nih.gov/pubmed/32660451
http://dx.doi.org/10.1186/s12885-020-07131-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359263/
https://www.ncbi.nlm.nih.gov/pubmed/32660451
http://dx.doi.org/10.1186/s12885-020-07131-6

Ejemplares similares